Oncotelic Therapeutics Inc Financials

OTLC

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows Oncotelic Therapeutics Inc (OTLC) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

2/9

Oncotelic Therapeutics Inc passes 2 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

0.16x

For every $1 of reported earnings, Oncotelic Therapeutics Inc generates $0.16 in operating cash flow (-$740K OCF vs -$4.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

-$4.5M

YoY+42.8%

Oncotelic Therapeutics Inc reported -$4.5M in net income in fiscal year 2024. This represents an increase of 42.8% from the prior year.

EPS (Diluted)

N/A

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$86K

YoY-49.5%

5Y CAGR+1.0%

10Y CAGR-44.3%

Oncotelic Therapeutics Inc held $86K in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

407M

YoY+2.0%

Oncotelic Therapeutics Inc had 407M shares outstanding in fiscal year 2024. This represents an increase of 2.0% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-54.8%

YoY+10.3pp

5Y CAGR-15.6pp

10Y CAGR-11.2pp

Oncotelic Therapeutics Inc's ROE was -54.8% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is up 10.3 percentage points from the prior year.

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

N/A

OTLC Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	N/A	$70K	N/A	N/A	$1.7M	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$61K-91.9%	$757K-79.3%	$3.7M-15.0%	$4.3M+213.6%	$1.4M
SG&A Expenses	$376K-34.5%	$574K-88.2%	$4.9M-11.2%	$5.5M+8.8%	$5.0M+70.9%	$2.9M
Operating Income	-$3.6M+46.2%	-$6.6M+31.6%	-$9.7M-6.5%	-$9.1M-20.3%	-$7.6M-75.9%	-$4.3M
Interest Expense	N/A	$1.0M-64.8%	$3.0M+48.3%	$2.0M+0.2%	$2.0M+166.6%	$749K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$4.5M+42.8%	-$7.9M-255.1%	$5.1M+154.3%	-$9.4M+1.2%	-$9.5M-43.2%	-$6.6M
EPS (Diluted)	N/A	$-0.02-300.0%	$0.01+133.3%	$-0.03	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$2970.0%	$297	N/A	$480+90.5%	$252-47.5%	$480	N/A
SG&A Expenses	$491K+647.0%	$66K-34.9%	$101K	N/A	$80K-16.7%	$96K-42.2%	$167K	N/A
Operating Income	-$491K-644.2%	-$66K+34.7%	-$101K	N/A	-$3.3M-3296.9%	-$97K+42.2%	-$167K	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	$235K	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$1.0M-476.9%	$278K+193.0%	-$299K	N/A	-$3.3M-1474.8%	-$210K+48.7%	-$409K	N/A
EPS (Diluted)	N/A	$0.00	$0.00	N/A	$-0.01	$0.00	$0.00	N/A

OTLC Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$26.7M-11.1%	$30.0M-16.9%	$36.1M+53.0%	$23.6M-0.2%	$23.7M-0.1%	$23.7M
Current Assets	$134K-50.6%	$272K-10.4%	$303K-51.7%	$627K+1.9%	$616K+125.5%	$273K
Cash & Equivalents	$86K-49.5%	$170K-29.4%	$241K-57.5%	$569K+20.0%	$474K+478.3%	$82K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$19K0.0%	$19K-3.9%	$20K0.0%	$20K0.0%	$20K-86.8%	$150K
Goodwill	$2.8M-53.4%	$6.0M-50.4%	$12.1M-42.7%	$21.1M0.0%	$21.1M0.0%	$21.1M
Total Liabilities	$19.2M+4.3%	$18.4M+8.7%	$16.9M+8.1%	$15.7M+31.7%	$11.9M+75.3%	$6.8M
Current Liabilities	$19.2M+16.3%	$16.5M-2.5%	$16.9M+9.5%	$15.5M+38.2%	$11.2M+64.9%	$6.8M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$8.3M-32.0%	$12.1M-37.5%	$19.4M+144.0%	$8.0M-32.4%	$11.8M-30.4%	$16.9M
Retained Earnings	-$38.0M-13.5%	-$33.5M-29.3%	-$25.9M+16.4%	-$31.0M-43.4%	-$21.6M-78.4%	-$12.1M

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Total Assets	$28.2M+5.5%	$26.7M0.0%	$26.7M0.0%	$26.7M-0.4%	$26.8M-10.5%	$29.9M-0.1%	$30.0M-0.1%	$30.0M
Current Assets	$1.6M+1072.3%	$138K+10.1%	$125K-6.9%	$134K-43.9%	$239K+24.5%	$192K-17.0%	$231K-14.9%	$272K
Cash & Equivalents	$409K+364.7%	$88K+11.2%	$79K-8.1%	$86K-42.2%	$149K+106.4%	$72K-61.8%	$189K+10.9%	$170K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$4K-79.0%	$19K0.0%	$19K0.0%	$19K0.0%	$19K0.0%	$19K0.0%	$19K0.0%	$19K
Goodwill	$2.8M0.0%	$2.8M0.0%	$2.8M0.0%	$2.8M0.0%	$2.8M-53.4%	$6.0M0.0%	$6.0M0.0%	$6.0M
Total Liabilities	$20.1M+4.1%	$19.3M-1.0%	$19.5M+1.5%	$19.2M+2.9%	$18.7M+1.2%	$18.4M-1.6%	$18.7M+1.7%	$18.4M
Current Liabilities	$20.1M+4.1%	$19.3M-1.0%	$19.5M+1.5%	$19.2M+17.4%	$16.4M+0.9%	$16.2M-1.9%	$16.5M0.0%	$16.5M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$9.1M+9.0%	$8.3M+3.5%	$8.0M-2.8%	$8.3M-6.8%	$8.9M-27.2%	$12.2M+2.7%	$11.8M-2.4%	$12.1M
Retained Earnings	-$39.1M-2.8%	-$38.1M+0.7%	-$38.3M-0.8%	-$38.0M-1.6%	-$37.4M-9.7%	-$34.1M-0.6%	-$33.9M-1.2%	-$33.5M

OTLC Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$740K+44.0%	-$1.3M+9.1%	-$1.5M+67.2%	-$4.4M-57.7%	-$2.8M-23.3%	-$2.3M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	$189K
Financing Cash Flow	$656K-47.5%	$1.3M+11.1%	$1.1M-75.2%	$4.5M+40.5%	$3.2M+48.5%	$2.2M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Operating Cash Flow	-$307K-143.4%	-$126K+24.4%	-$167K-60.7%	-$104K+27.5%	-$143K+45.3%	-$262K-13.1%	-$231K+37.9%	-$373K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$628K+365.2%	$135K-15.6%	$160K+290.2%	$41K-81.4%	$220K+51.7%	$145K-42.0%	$250K-9.1%	$275K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

OTLC Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	-9497.2%	N/A	N/A	-435.7%	N/A
Net Margin	N/A	-11290.1%	N/A	N/A	-545.9%	N/A
Return on Equity	-54.8%+10.3pp	-65.1%-91.4pp	26.3%+144.3pp	-118.0%-37.3pp	-80.7%-41.5pp	-39.3%
Return on Assets	-17.0%+9.4pp	-26.3%-40.4pp	14.1%+53.9pp	-39.8%+0.4pp	-40.2%-12.1pp	-28.0%
Current Ratio	0.010.0	0.020.0	0.02-0.0	0.04-0.0	0.06+0.0	0.04
Debt-to-Equity	2.33+0.8	1.52+0.6	0.87-1.1	1.97+1.0	1.01+0.6	0.40
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-11.6%-14.9pp	3.4%+7.1pp	-3.7%	N/A	-37.3%-35.6pp	-1.7%+1.7pp	-3.5%	N/A
Return on Assets	-3.7%-4.8pp	1.0%+2.2pp	-1.1%	N/A	-12.3%-11.6pp	-0.7%+0.7pp	-1.4%	N/A
Current Ratio	0.08+0.1	0.010.0	0.010.0	0.010.0	0.010.0	0.010.0	0.010.0	0.02
Debt-to-Equity	2.22-0.1	2.32-0.1	2.43+0.1	2.33+0.2	2.11+0.6	1.52-0.1	1.58+0.1	1.52
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: The current ratio is below 1.0 (0.01), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Resverlogix RVXCF

$23.0M

Finch Therapeutics Group, Inc. FNCH

$5.0M

Biomind Labs Inc BMNDF

$5.0M

ACCUSTEM SCIENCES INC ACUT

$5.1M

Harvard Apparatus Regenerative Technology Inc. HRGN

$29.5M

Frequently Asked Questions

Is Oncotelic Therapeutics Inc profitable?

No, Oncotelic Therapeutics Inc (OTLC) reported a net income of -$4.5M in fiscal year 2024.

What is Oncotelic Therapeutics Inc's return on equity (ROE)?

Oncotelic Therapeutics Inc (OTLC) has a return on equity of -54.8% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.

What is Oncotelic Therapeutics Inc's operating cash flow?

Oncotelic Therapeutics Inc (OTLC) generated -$740K in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Oncotelic Therapeutics Inc's total assets?

Oncotelic Therapeutics Inc (OTLC) had $26.7M in total assets as of fiscal year 2024, including both current and long-term assets.

How many shares does Oncotelic Therapeutics Inc have outstanding?

Oncotelic Therapeutics Inc (OTLC) had 407M shares outstanding as of fiscal year 2024.

What is Oncotelic Therapeutics Inc's current ratio?

Oncotelic Therapeutics Inc (OTLC) had a current ratio of 0.01 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.

What is Oncotelic Therapeutics Inc's debt-to-equity ratio?

Oncotelic Therapeutics Inc (OTLC) had a debt-to-equity ratio of 2.33 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Oncotelic Therapeutics Inc's return on assets (ROA)?

Oncotelic Therapeutics Inc (OTLC) had a return on assets of -17.0% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Oncotelic Therapeutics Inc's cash runway?

Based on fiscal year 2024 data, Oncotelic Therapeutics Inc (OTLC) had $86K in cash against an annual operating cash burn of $740K. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Oncotelic Therapeutics Inc's Piotroski F-Score?

Oncotelic Therapeutics Inc (OTLC) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Oncotelic Therapeutics Inc's earnings high quality?

Oncotelic Therapeutics Inc (OTLC) has an earnings quality ratio of 0.16x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.